Leuprolide plus donepezil may stabilize memory loss in Alzheimer's disease
the ONA take:
According to a new study published in the Journal of Alzheimer's Disease, researchers have found that leuprolide, a drug commonly used for androgen deprivation therapy for patients with prostate cancer, stabilized memory loss for a year in women with Alzheimer's disease.
For the study, researchers enrolled 109 women with mild to moderate Alzheimer's disease. Some women were treated with high-dose leuprolide acetate and donepezil, an acetylcholinesterase inhibitor that treats symptoms of Alzheimer's disease.
Other patients received an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo. Results showed that those treated with donepezil and high-dose leuprolide had nearly no decline in their ADAS-cog score, a memory test, while those treated with an acetylcholinesterase inhibitor plus low-dose leuprolide or placebo experienced declines after 1 year.
Previous studies have suggested the leuprolide has protective benefits for Alzheimer's disease. One study found that men treated with leuprolide for prostate cancer were 34-55% less likely to develop Alzheimer's disease compared with men who did not receive the injection.
The researchers suggest that this promising drug combination should be tested in patients with early and late stages of the disease, but because the company that initially conducted this research is now out of business, it is unclear whether this therapy will be further developed.
Leuprolide stabilized memory loss for a year in women with Alzheimer's disease.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Patients and Caregivers Worry About Cost of Cancer Care
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Seeking an Explanation for the Lack of Research Focused in Pediatric Oncology Therapeutics
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|